Garry D, Figueroa R, Kalish R B, Catalano C J, Maulik D
Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York, USA.
J Matern Fetal Neonatal Med. 2003 Apr;13(4):254-9. doi: 10.1080/jmf.13.4.254.259.
To compare the safety and efficacy of vaginal misoprostol versus dinoprostone vaginal inserts for cervical ripening and labor induction.
Two hundred singleton gestations with an indication for cervical ripening and induction of labor were randomized to receive either 50 microg of misoprostol intravaginally every 3 h or a 10-mg dinoprostone vaginal insert every 12 h for a maximum of 24 h. Statistical analysis included Student's t test, the Mann-Whitney U test, chi2 analysis and Fisher's exact test.
Ninety-seven women received vaginal misoprostol while 89 women received the dinoprostone vaginal insert. Fourteen women were removed from the study after randomization. The interval from start of induction to vaginal delivery (794.5 +/-408 min vs. 1005.3 +/- 523 min; p < 0.02) was significantly shorter in the misoprostol group. Women receiving misoprostol were more likely to deliver vaginally both in < 12 h (44% vs. 12%; p < 0.0001) and < 24 h (68% vs. 38%; p < 0.001). A non-reassuring fetal heart rate tracing was the indication for 71.4% (20/28) of Cesarean deliveries in the misoprostol group compared to 40% (14/35) in the dinoprostone group (p = 0.03). There were no significant differences in neonatal outcomes.
Intravaginal misoprostol and dinoprostone are safe and effective medications for use in cervical ripening before labor induction. Misoprostol results in a shorter interval from induction to delivery. However, Cesarean delivery for a non-reassuring fetal heart rate tracing was more common with misoprostol.
比较阴道用米索前列醇与地诺前列酮阴道栓剂在促宫颈成熟及引产方面的安全性和有效性。
将200例有促宫颈成熟及引产指征的单胎妊娠患者随机分组,一组每3小时阴道给予50微克米索前列醇,另一组每12小时阴道给予10毫克地诺前列酮阴道栓剂,最长用药24小时。统计分析包括学生t检验、曼-惠特尼U检验、卡方分析和费舍尔精确检验。
97例妇女接受阴道用米索前列醇,89例妇女接受地诺前列酮阴道栓剂。随机分组后有14例妇女退出研究。米索前列醇组从引产开始至阴道分娩的间隔时间(794.5±408分钟 vs. 1005.3±523分钟;p<0.02)明显更短。接受米索前列醇的妇女在<12小时(44% vs. 12%;p<0.0001)和<24小时(68% vs. 38%;p<0.001)时更有可能经阴道分娩。米索前列醇组剖宫产的指征中胎儿心率监护异常占71.4%(20/28),而地诺前列酮组为40%(14/35)(p = 0.03)。新生儿结局无显著差异。
阴道用米索前列醇和地诺前列酮是引产促宫颈成熟的安全有效药物。米索前列醇可使引产至分娩的间隔时间更短。然而,米索前列醇用于胎儿心率监护异常而行剖宫产更为常见。